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Background and purpose   Hydroxyapatite (HA) coating stimu-
lates  the  osseointegration  of  cementless  orthopedic  implants. 
Recently,  locally  released  osteogenic  growth  factors  have  also 
been shown experimentally to stimulate osseointegration so that 
bone fills gaps around orthopedic implants. Here, we have com-
pared the effect of local release of TGF-β1 and IGF-1 with that of 
hydroxyapatite coating on implant fixation. 
Method   Weight-bearing implants with a 0.75-mm surround-
ing gap were inserted bilaterally in the knees of 10 dogs. Growth 
factors were incorporated in a biodegradable poly(D,L-lactide) 
coating on porous coated titanium implants. Plasma-sprayed HA 
implants served as controls. The dogs were killed at 4 weeks and 
the implants were evaluated by mechanical push-out test and by 
histomorphometry.
Results   There was no difference in any of the mechanical 
parameters.  Bone  ongrowth  was  3-fold  higher  for  HA-coated 
implants (p < 0.001). For growth factor-coated implants, bone 
volume was 26% higher in the inner half of the gap and 28% 
higher in the outer half compared to HA (p < 0.03).
Interpretation   The mechanical fixation of porous-coated tita-
nium implants with local growth factor release is comparable to 
that of HA coating. While HA mainly stimulated bone ongrowth, 
local release of TGF-β1 and IGF-1 stimulated gap healing.  

The long-term fixation of cementless total hip replacements 
(THRs) is positively affected by rapid bony integration. This 
has been confirmed by RSA studies that have concluded that 
early implant migration is a strong predictor of early loosen-
ing (Karrholm et al. 1994, Hauptfleisch et al. 2006).
Implants with a hydroxyapatite (HA) coating stimulate bone 
ingrowth to implants. The highly osteoconductive nature of 
HA coatings has been demonstrated experimentally (Soballe et 
al. 1990, 1992), and superior longevity has been demonstrated 
clinically (Soballe et al. 1993, Capello et al. 2006, Kelly et 
al. 2006). Recently, new adjuvant therapies using osteogenic 
growth  factors  have  been  introduced.  Experimental  studies 
have shown that local growth factor treatment can stimulate 
osseointegration and gap healing of orthopedic implants (Lam-
berg et al. 2006, Sumner et al. 2006). Some of these treatments 
have also proven useful in fracture healing and spinal fusion 
(Schmidmaier et al. 2001a, Kandziora et al. 2002).
We have previously shown that the combination of trans-
forming growth factor β1 (TGF-β1) and insulin-like growth 
factor 1 (IGF-1) in a biodegradable poly(D,L-lactide) coat-
ing markedly increases the fixation and osseointegration of 
porous coated titanium implants in an unloaded 1-mm gap 
model (Lamberg et al. 2006). To follow up on the comparison 
with the negative control group (Ti), we next compared local 
growth factor treatment pairwise with HA coating, a known 
effective stimulator of osseointegration. 
In a paired study using dogs, we compared porous-coated 
implants with 2 different coatings applied to the base tita-
nium alloy, in a loaded 0.75-mm gap model in the knee. In 
one group, implants were coated with a biodegradable carrier, 
poly(D,L-lactide), containing a combination of TGF-β1 and 
IGF-1. In the other group, the implants were plasma-sprayed 
with hydroxyapatite coating. We hypothesized that the growth 
factor coating would result in better mechanical fixation and 
more bone on and around the implant.
Material and methods 
Study design
Following approval of the institutional Animal Care and Use 
committee, we performed a paired study in 10 skeletally mature 
purpose-bred hound dogs with a mean weight of 22 (SD 1.2) 500  Acta Orthopaedica 2009; 80 (4): 499–504
kg. We used an established model (Soballe et al. 1992) in which 
the implants are weight bearing and surrounded by a circum-
ferential gap of 0.75 mm (Figure 1). Implants were inserted 
in the distal femur, in a cancellous bone site oriented along 
the medial condyles’ major weight-bearing axis. The growth 
factor-coated implants were inserted in the right femoral con-
dyle, and the HA-coated control implants were inserted in the 
left femoral condyle. The observation period was 4 weeks.
Coatings
The coatings were applied to cylindrical, porous-coated tita-
nium (Ti-6Al-4V) implants measuring nominally 6 mm × 10 
mm (Biomet Inc., Warsaw IN). In our laboratory, we mixed 
sterile filtered poly(D,L-lactide) (Resomer 203; Boehringer 
Ingelheim,  Germany)  and  carrier-free  recombinant  human 
TGF-β1  and  IGF-1  (R&D  Systems,  Minneapolis  MN)  in 
ethyl acetate to a w/w ratio of 1% for the TGF-β1 and 5% 
for the IGF-1. The implants were dipped in the solution and 
air-dried for 1 min before being dipped again. Based on ear-
lier work, we estimated the coating to be 10–20 microns thick 
and that each implant contained 28 µg TGF-β1 and 140 µg 
IGF-1 (Lamberg et al. 2006). The control implants received a 
plasma-sprayed HA coating with a thickness of approximately 
40–70 µm (Biomet).
Surgery
We performed the surgery with the dogs under general anes-
thesia. The incision was made medial to the patella, and the 
most distal point of the medial femoral condyle was identified. 
7.5-mm holes were drilled in the medial femoral condyle. A 
stabilizing anchor screw with a central threaded pin was first 
inserted, and then the implant was screwed onto the piston of 
the anchor screw. This resulted in a 0.75-mm circumferential 
gap around the implant. A centralizing ring and polyethyl-
ene plug was mounted to secure the position of the implant 
concentric within the gap (Figure 1). The polyethylene plug 
extended 1 mm into the joint, transmitting load to the implant 
in each gait cycle or knee flexion. The soft tissue was closed in 
layers. All animals were fully weight-bearing within 24 h. The 
animals received the antibiotic cefuroxime (Rocephin, Roche 
Pharmaceutical)  prophylactically  (1  g  intravenously  before 
surgery and 1 g intramuscularly daily for 3 days). The dogs 
were evaluated daily by the institutional veterinarian. 
Preparation
Pending preparation, the bone-implant specimens were kept 
frozen at –20°C. To separate the specimens for mechanical 
testing from those for histomorphometry, the bone-implant 
specimens were cut transversely with a water-cooled diamond 
band saw. The outermost 3.5 mm was used for mechanical 
testing and the remaining 6.5 mm was used for histomorphom-
etry. The latter was dehydrated in graded ethanol (70–100%) 
with 0.4% basic fuchsin and then embedded in methylmeth-
acrylate. 
Mechanical testing
Implants were tested to failure by a push-out test on an Instron 
Universal Test Machine (Model 4302; Instron, High Wycombe, 
UK). The specimens were placed on a metal support jig with 
a 7.4-mm circular opening. A preload of 2 N was applied, to 
ensure contact with the implant. The displacement rate was 
5.0 mm/min. Maximum shear strength (MPa), apparent shear 
stiffness (MPa/mm), and energy to failure (J/m2) were calcu-
lated from the recorded load-displacement data. The analysis 
was performed in blinded fashion.
Histomorphometry
The specimens underwent random vertical sectioning on a 
Leiden microtome (Leiden, Holland), and were counterstained 
with 2% light green (Overgaard et al. 2000). The analyses 
were done with Cast grid software (Olympus). The obvious 
presence of hydroxyapatite on the control implants made true 
blinding impossible, but the examiner did not know which 
implant was the pair match. We quantified bone and fibrous 
tissue by stereological principles (Gundersen et al. 1988). The 
ongrowth was estimated using line interception technique and 
the gap volume fractions were estimated by point interception 
technique. The gap was divided into 2 zones: the inner zone 
adjacent to the implant surface, and the outer zone adjacent to 
the edge of the drill hole (Figure 2).
Statistics
As an aid in designing this study, we performed a sample-size 
calculation based on the assumption that the mean change is 
50% and an SD of the change is 50%. The primary endpoint for 
the sample-size calculation was the maximum shear strength. 
Figure 1. Illustrations of the model. The polyethylene plug transferring 
load from the tibial cartilage to the implant is not shown. The implant is 
surrounded by a 0.75-mm gap, and it is loaded during each gait cycle. 
In addition, there is a constant flow of joint fluid passing the surface. 
The HA-coated implants were inserted in the left femur and the growth 
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With a risk of type 1 error of 5% and a power of 80%, we 
needed 8 animals in the study. In order to allow for exclusions 
due to animal deaths, mistakes in preparation of specimens, 
and other unforeseen incidents, this number was increased. 
Stata 8.0 software (StataCorp, College Station, TX) was used 
for the statistical calculations. The paired data were analyzed 
by the paired t-test. We considered two tailed p-values less 
than 0.05 to be statistically significant. All data are presented 
as mean with 95% confidence interval (CI).
Results 
All dogs were fully mobilized within 24 h and no signs of 
infections were observed. Cultures taken from the implanta-
tion site at retrieval were all without bacterial growth. We had 
to exclude 2 implant pairs from the mechanical testing, 1 due 
to a surgical malalignment of the implant and 1 due to a tech-
nical error during preparation.
The mechanical push-out test found all implants to be well 
fixed, with shear strength ranging from 2.5 to 5 MPa. There 
were no statistically significant differences in any of the 3 
mechanical parameters (Figure 3 and Table 1).
In  contrast  to  the  push-out  test,  the  histomorphometric 
analysis showed differences in tissue distribution around the 
implants. Bone ongrowth to the implants was 3-fold higher for 
HA-coated implants (p < 0.001) (Table 2). There was ongrowth 
of fibrous tissue in 4 of the 10 HA-coated implants (up to 8%), 
and no fibrous tissue on the growth factor-coated implants (p = 
0.05) (Figure 4). In the inner half of the gap, the bone volume 
Figure  2.  Images  from  histomorphometry.  A.  hydroxyapatite-coated 
implant. B. Growth factor-coated implant. The lines indicate the inner 
and  outer  zones  where  the  tissue  volume  is  measured.  Ongrowth 
is defined as tissue in direct contact with the implant surface or the 
hydroxyapatite coating. 
   A    B
Table 1. Mechanical data (n = 8; 2 excluded). No difference was 
seen in any of the mechanical parameters (p ≥ 0.23). The data are 
presented as mean (95% CI)
  Energy to failure  Shear stiffness 
  J/m²   Mpa/mm
Hydroxyapatite   561 (340–781)   19.9 (16.2–23.5)
TGF-β1 and IGF-1   713 (585–842)   18.7 (16.0–21.5)
Table 2. Histomorphometric data for bone. Data are presented as 
mean (95% CI) percentage
  Ongrowth   Inner gap
TGF-β1 and IGF-1   14 (11–16)   29 (27–32) b
Hydroxyapatite   44 (40–48 ) a   23 (19–27)
a p < 0.001; b p = 0.01.
Figure 3. Line plot of maximum shear strength. Paired data are shown 
interconnected. (p = 0.5).
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Figure 4. Graph showing percentage of fibrous tissue on the implant 
surface (ongrowth), and in the inner gap (p = 0.05). Paired data are 
shown interconnected. HA: Hydroxyapatite, GF: growth factor.
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fraction was 26% higher in the growth factor-coated implant 
group (p = 0.01) (Table 2). In the outer half of the gap, the 
bone volume fraction was 28% higher in the growth factor-
coated implant group (p = 0.03) (Figure 5). There were no 
signs of residual polymer on the implant surfaces.
Discussion
In this study we compared the effects of local release of TGF-
β1 and IGF-1 with that of a hydroxyapatite coating on the 
fixation of weight-bearing implants surrounded by a circum-
ferential gap. Although we did not find any difference in the 
mechanical fixation, the effect on the surrounding tissue was 
different with the two interventions. While the growth fac-
tors primarily stimulated bone in the gap, the HA coating had 
superior bone ongrowth.
We  used  an  experimental  animal  model  that  attempts  to 
mimic the cancellous bone fixation of clinical implants. The 
implants are weight-bearing and their intraarticular location 
results in a flow of synovial fluid along the implant interface. 
The main idea of this model is to test whether a treatment 
will enhance the initial implant fixation, and thus prevent early 
loosening. The observation period of 4 weeks has been shown 
to detect differences in early fixation in this model (Soballe et 
al. 2003, 2004). We used a paired design, thus eliminating the 
inter-individual variation between animals.
As with all other experimental models, this model also has 
limitations. The loading is mainly in shear and does not include 
the rotational forces that also apply to human implants. The 
dog has a bone turnover which is 2–3 times higher than that 
in humans. This may influence the effect of certain treatments. 
Moreover, the implants are simplified in shape and size and 
do not include fixation points of both cancellous and cortical 
Figure 5. Graph showing the data for the outer zone bone volume (p = 
0.03). Paired data are shown interconnected.
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bone. However, this allows implantation in a highly controlled 
environment and permits unbiased histological evaluation. 
The histological analysis showed that the solid fixation in 
both groups was obtained in a different way for each group: 
the HA-coated implants had a greater surface bone ongrowth, 
whereas the growth factor-coated Ti implants had greater new 
bone formation in the surrounding gap. 
The effect of local release of TGF-β1 and IGF-1 on the 
tissue  response  was  different  than  for  HA.  In  accordance 
with previous studies (Lamberg et al. 2006), no fibrous tissue 
ongrowth was found on any implant with TGF-β1 and IGF-
1. Without adjuvant therapy, a high degree of fibrous tissue 
anchorage would be expected on titanium implants in this 
implant model (Soballe et al. 1992, Elmengaard et al. 2005). 
We believe that the elimination of fibrous tissue on the inter-
face is not an effect related to the poly(D,L-lactide) scaffold. 
A parallel study has shown no difference in fibrous tissue 
ongrowth between poly(D,L-lactide)-coated and control tita-
nium implants (unpublished data). To our knowledge, no other 
adjuvant treatment has been shown experimentally to stimu-
late gap healing around titanium implants better than HA.
Applications combining 2 or more growth factors may be 
more favorable due to additive or synergistic effects on bone 
formation.  TGF-β1  and  IGF-1  are  both  highly  expressed 
during bone growth (Dequeker et al. 1993, Nicolas et al. 1994, 
Lammens et al. 1998, Eingartner et al. 1999, Pfeilschifter et 
al. 1999, Kveiborg et al. 2001). A synergistic effect of TGF-β1 
and IGF-1 on bone healing has been reported (Schmidmaier 
et al. 2003). Our study does not allow us to make conclusions 
on the contribution of each component to the result. However, 
the overall effect of the combined growth factors was higher 
compared to historic data from studies using the same model 
and single administration of TGF-β1 (Lind et al. 1996a, b).
We used a polymer for controlled release of the growth 
factors. The poly(D,L-lactide) has been used successfully as 
a drug carrier (Schmidmaier et al. 2001b, Rose et al. 2004). 
Polylactides are also used to make screws and plates for frac-
ture treatment, and are generally considered safe. This delivery 
system has advantages over other methods such as simple sur-
face adsorption of growth factors and collagen sponges, as it 
has been documented to be mechanically stable (Schmidmaier 
et al. 2001b) and thereby able to resist the forces of implanta-
tion. In addition, it is generally accepted that the majority of 
the growth factors most likely remain in the scaffold until the 
bleeding from the bone has ceased. Elution studies have shown 
a release profile of 50% release within 48 h, with growth fac-
tors detectable for several weeks thereafter. In contrast to the 
studies of fracture healing in a rat model (Schmidmaier et al. 
2001b), there was no polymer left on our implants at the end 
of the observation period. The amount of growth factor used 
depends on the size of the implants, as the growth factors are 
administered in a specific w/w ratio to the poly(D,L-lactide) 
scaffold. The w/w ratio that we used was based on previous 
experience (Kandziora et al. 2003, Lamberg et al. 2006). It is Acta Orthopaedica 2009; 80 (4): 499–504  503
possible that even better results would be obtained with differ-
ent ratios, and this is the subject of further investigation.
Interpretation
The mechanical fixation obtained with local release of TGF-
β1 and IGF-1 is comparable to that of an HA coating. The 
mechanical fixation was achieved in different ways, as HA 
stimulated bone ongrowth while TGF -β1 and IGF-1 signifi-
cantly increased gap healing. The results of this study suggest 
that controlled local growth factor release has the potential to 
be used in clinical situations in which a more general stimula-
tion of bone is required, e.g. in revision arthroplasties or pseu-
doarthrosis. Given their different effects, a combination of the 
two coatings would be an interesting subject for further inves-
tigation. It is necessary to keep in mind that hydroxyapatite 
has had a long and successful history of clinical implemen-
tation, while growth factors may have unknown side effects 
when used clinically. 
AL: protocol, surgery, data collection, and preparation of manuscript. JEB, 
KS, and BE: protocol, surgery, and revision of manuscript. JB: protocol and 
manuscript revision.
The authors thank Anette Milton, Jane Pauli, and Feng Ya Mei for technical 
assistance. Niels Trolle Andersen of the Department of Biostatistics, Univer-
sity of Aarhus, provided invaluable help with statistics. The Interdisciplin-
ary Research Group, Nanoscience and Biocompatibility, Danish Research 
Agency,  provided  financial  support  (grant  no.2052-01-0049).  The  Danish 
Rheumatism Association, Kurt Bønnelycke og Hustru Grethe Bønnelyckes 
Fond, and the Max og Anna Friedmanns Legat til Sygdomsbekæmpelse also 
kindly supported the study.
Biomet Inc. donated the implants used in this study.
No competing interests declared.
 
Capello W N, D’Antonio J A, Jaffe W L, Geesink R G, Manley M T, Feinberg 
J R. Hydroxyapatite-coated femoral components - 15-year minimum fol-
lowup. Clin Orthop 2006; [453]: 75-80.
Dequeker J, Mohan S, Finkelman R D, Aerssens J, Baylink D J. Generalized 
osteoarthritis associated with increased insulin-like growth factor types I 
and II and transforming growth factor beta in cortical bone from the iliac 
crest. Possible mechanism of increased bone density and protection against 
osteoporosis. Arthritis Rheum 1993; 36: 1702-8.
Eingartner C, Coerper S, Fritz J, Gaissmaier C, Koveker G, Weise K. Growth 
factors in distraction osteogenesis. Immuno-histological pattern of TGF-
beta1 and IGF-I in human callus induced by distraction osteogenesis. Int 
Orthop 1999; 23: 253-9.
Elmengaard B, Bechtold J E, Soballe K. In vivo effects of RGD-coated tita-
nium implants inserted in two bone-gap models. J Biomed Mater Res A 
2005; 75(2): 249-55.
Gundersen H J, Bendtsen T F, Korbo L, Marcussen N, Moller A, Nielsen 
K, Nyengaard J R, Pakkenberg B, Sorensen F B, Vesterby A. Some new, 
simple and efficient stereological methods and their use in pathological 
research and diagnosis. APMIS 1988; 96: 379-94.
Hauptfleisch J, Glyn-Jones S, Beard D J, Gill H S, Murray D W. The prema-
ture failure of the Charnley Elite-Plus stem: a confirmation of RSA predic-
tions. J Bone Joint Surg (Br) 2006; 88: 179-83.
Kandziora F, Schmidmaier G, Schollmeier G, Bail H, Pflugmacher R, Gorke 
T, Wagner M, Raschke M, Mittlmeier T, Haas N P. IGF-I and TGF-beta1 
application by a poly-(D,L-lactide)-coated cage promotes intervertebral 
bone matrix formation in the sheep cervical spine. Spine 2002; 27: 1710-
23.
Kandziora F, Pflugmacher R, Scholz M, Schafer J, Schollmeier G, Schmid-
maier G, Duda G, Raschke M, Haas N P. Dose-dependent effects of com-
bined IGF-I and TGF-beta1 application in a sheep cervical spine fusion 
model. Eur Spine J 2003; 12: 464-73.
Karrholm J, Borssen B, Lowenhielm G, Snorrason F. Does early micromotion 
of femoral stem prostheses matter? 4-7-year stereoradiographic follow-up 
of 84 cemented prostheses. J Bone Joint Surg (Br) 1994; 76: 912-7.
Kelly S J, Incavo S J, Beynnon B. The use of a hydroxyapatite-coated primary 
stem in revision total hip arthroplasty. J Arthroplasty 2006; 21: 64-71.
Kveiborg M, Flyvbjerg A, Eriksen E F, Kassem M. Transforming growth 
factor-beta1 stimulates the production of insulin-like growth factor-I and 
insulin-like growth factor-binding protein-3 in human bone marrow stro-
mal osteoblast progenitors. J Endocrinol 2001; 169: 549-61.
Lamberg A, Schmidmaier G, Soballe K, Elmengaard B. Locally delivered 
TGF-beta 1 and IGF-1 enhance the fixation of titanium implants - A study 
in dogs. Acta Orthopaedica 2006; 77: 799-805.
Lammens J, Liu Z, Aerssens J, Dequeker J, Fabry G. Distraction bone heal-
ing versus osteotomy healing: a comparative biochemical analysis. J Bone 
Miner Res 1998; 13: 279-86.
Lind M, Overgaard S, Nguyen T, Ongpipattanakul B, Bunger C, Soballe K. 
Transforming growth factor-beta stimulates bone ongrowth. Hydroxyapa-
tite-coated implants studied in dogs. Acta Orthop Scand 1996a; 67: 611-6.
Lind M, Overgaard S, Ongpipattanakul B, Nguyen T, Bunger C, Soballe K. 
Transforming growth factor-beta 1 stimulates bone ongrowth to weight-
loaded tricalcium phosphate coated implants: an experimental study in 
dogs. J Bone Joint Surg (Br) 1996b; 78: 377-82.
Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman R D, Baylink D J, Farley 
J R. Age-related decreases in insulin-like growth factor-I and transforming 
growth factor-beta in femoral cortical bone from both men and women: 
implications for bone loss with aging. J Clin Endocrinol Metab 1994; 78: 
1011-6.
Overgaard S, Soballe K, Jorgen H, Gundersen G. Efficiency of systematic 
sampling in histomorphometric bone research illustrated by hydroxyapa-
tite-coated implants: optimizing the stereological vertical-section design. J 
Orthop Res 2000; 18: 313-21.
Pfeilschifter J, Erdmann J, Storch S, Ziegler R, Weinreb M. Changes in the 
concentration  of  insulin-like  growth  factor  I  and  transforming  growth 
factor beta1 in rat femoral bone during growth. Calcif Tissue Int 1999; 
64: 78-82.
Rose F R, Hou Q, Oreffo R O. Delivery systems for bone growth factors 
- the new players in skeletal regeneration. J Pharm Pharmacol 2004; 56) 
415-27.
Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, 
Flyvbjerg A, Haas N P, Raschke M. Local application of growth factors 
(insulin-like growth factor-1 and transforming growth factor-beta1) from a 
biodegradable poly(D,L-lactide) coating of osteosynthetic implants accel-
erates fracture healing in rats. Bone 2001a; 28: 341-50.
Schmidmaier G, Wildemann B, Stemberger A, Haas N P, Raschke M. Biode-
gradable poly(D,L-lactide) coating of implants for continuous release of 
growth factors. J Biomed Mater Res 2001b; 58: 449-55.
Schmidmaier G, Wildemann B, Gabelein T, Heeger J, Kandziora F, Haas N P, 
Raschke M. Synergistic effect of IGF-I and TGF-beta1 on fracture healing 
in rats: single versus combined application of IGF-I and TGF-beta1. Acta 
Orthop Scand 2003; 74: 604-10.
Soballe K, Hansen E S, Brockstedt-Rasmussen H, Pedersen C M, Bunger 
C. Hydroxyapatite coating enhances fixation of porous coated implants. A 
comparison in dogs between press fit and noninterference fit. Acta Orthop 
Scand 1990; 61: 299-306.504  Acta Orthopaedica 2009; 80 (4): 499–504
Soballe K, Hansen E S, Rasmussen H, Jorgensen P H, Bunger C. Tissue 
ingrowth into titanium and hydroxyapatite-coated implants during stable 
and unstable mechanical conditions. J Orthop Res 1992; 10: 285-99.
Soballe K, Toksvig-Larsen S, Gelineck J, Fruensgaard S, Hansen E S, Ryd 
L, Lucht U, Bunger C. Migration of hydroxyapatite coated femoral pros-
theses. A Roentgen Stereophotogrammetric study. J Bone Joint Surg (Br) 
1993; 75: 681-7.
Soballe K, Mouzin O R, Kidder L A, Overgaard S, Bechtold J E. The effects of 
hydroxyapatite coating and bone allograft on fixation of loaded experimen-
tal primary and revision implants. Acta Orthop Scand 2003; 74: 239-47.
Soballe K, Jensen T B, Mouzin O, Kidder L, Bechtold J E. Differential effect 
of a bone morphogenetic protein-7 (OP-1) on primary and revision loaded, 
stable implants with allograft. J Biomed Mater Res 2004; 71A: 569-76.
Sumner D R, Turner T M, Urban R M, Virdi A S, Inoue N. Additive enhance-
ment of implant fixation following combined treatment with rhTGF-beta2 
and rhBMP-2 in a canine model. J Bone Joint Surg (Am) 2006; 88: 806-
17.
 
 
 
 
 